Didem Turgut
Hacettepe University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Didem Turgut.
Nephron Clinical Practice | 2011
Aysun Aybal Kutlugun; Mustafa Arici; Tolga Yildirim; Didem Turgut; Rahmi Yilmaz; Mahmut Altindal; Bulent Altun; Yunus Erdem; Ünal Yasavul; Cetin Turgan
Objective: To determine daily sodium intake in ‘real practice’ in a large group of chronic kidney disease (CKD) patients who were under regular follow-up in a nephrology clinic. Methods: A total of 373 consecutive outpatients with CKD stages 1–5 (not on dialysis; men: 52.3%, mean age: 51.6 ± 15.4 years) were included in the study. All patients had at least 3 or more nephrology visits and received information on reducing their sodium intake. Data for systolic and diastolic blood pressure, number of antihypertensive medications and 2 consecutive 24-hour urinary sodium levels were obtained from the patients’ medical records. Results: The mean 24-hour urinary sodium levels of 2 consecutive urine samples were 168.8 ± 70.3 and 169.3 ± 67.4 mEq/day (p > 0.05). Only 14.7% of the patients had a sodium excretion <100 mmol/day. There was no difference in daily sodium intake from stages 1 to 4, but it was significantly lower in stage 5 (126.6 ± 60.5 mEq/day, p < 0.05). No relation was found between 24-hour urinary sodium output, number of antihypertensives or thiazide use. Conclusions: This study showed that almost 85% of CKD patients under regular nephrologic care were consuming more sodium than the recommended level. More robust measures should be devised to increase patient and physician compliance with reducing sodium intake in CKD.
Nefrologia | 2015
Nihal Ozkayar; Serhan Piskinpasa; Fatma Akyel; Didem Turgut; Mesudiye Bulut; Turan Turhan; Fatih Dede
We aimed to investigate the role of cathepsin D, an inflammatory and atherosclerotic mediator, in endothelial dysfunction in chronic kidney disease. The study included 65 patients with stage 2–4 chronic kidney disease (35 females, 30 males; mean age, 55.8±15.6 years). Serum creatinine and cathepsin D levels and glomerular filtration rates (GFRs) were determined, and brachial flow-mediated dilation (FMD) percentage was measured by two-dimensional gray scale and color flow Doppler and vascular imaging. FMD ≤6% was considered to indicate endothelial dysfunction. Mean GFR, median creatinine levels, and median cathepsin D levels were 40.2±11.2mL/min/1.73m2, 1.7mg/dL, and 819.75ng/mL, respectively. Endothelial dysfunction was present in 30 of the 65 patients (46.2%). There was a significant difference between groups with and without endothelial dysfunction in terms of cathepsin D (p=0.001) and creatinine (p=0.03) levels, and negative and significant correlations were found between brachial artery FMD% and cathepsin D (r=−0.359, p=0.003) and creatinine (r=−0.304, p=0.014) levels. Cathepsin D, which is known to be associated with atherosclerosis, may play a role in the process of endothelial dysfunction. Further studies are essential to determine the exact function of cathepsin D in endothelial dysfunction in chronic kidney disease and to determine its value as a tool for early diagnosis and target for treatment of cardiovascular diseases in patients with chronic kidney disease.
International Journal of Artificial Organs | 2016
Ezgi Coskun Yenigun; Cenk Aypak; Didem Turgut; Mehmet Zafer Aydin; Fatih Dede
Background There is a strong association between chronic kidney disease (CKD) and cardiovascular events. Increased arrhythmia risk in kidney disease is one of the main predominant factors in increased mortality and sudden cardiac death. To estimate this risk, noninvasive measurement of repolarization abnormalities including QT interval and its heart rate-corrected value (QTc) with surface ECG, are commonly used parameters in clinical practice. The aim of this study is to examine the effect of CKD-related problems – mainly acidosis – on QT intervals. Methods 30 patients with stage 3–5 CKD whose serum bicarbonate concentrations below 20 mmol/L were included in the study. Alkali therapy with oral sodium bicarbonate was used to maintain the serum bicarbonate concentration in the normal range. At the beginning all patients had sinus rhythm on surface ECG records. Kidney function tests including serum urea, serum creatinine, uric acid, blood gas analysis, and electrolytes were analyzed at the beginning and at the end of alkali treatment. All patients underwent 12 lead-ECGs, recorded simultaneously. One cardiologist examined the ECGs manually in terms of QT intervals, corrected for heart rate (QTc), QT dispersion (QTd) and corrected QT dispersion (QTcd). Results There were statistically significant differences in QT intervals, QTc, QTd and QTcd before and after sodium bicarbonate treatment. The correlation analyses revealed that there were significant negative correlations in pretreatment ECGs of patients between QTd and QTcd with blood pH level. Multivariate analyses between biochemical parameters and QTd-QTcd intervals have revealed that pH was related to QTd and QTc. Conclusions This study demonstrated that QT intervals on surface ECG are decreased after treatment of acidosis in CKD. Further studies are needed to show whether increased QT intervals cause ventricular arrhythmias in CKD.
Rheumatology International | 2013
Nihal Ozkayar; Serhan Piskinpasa; Fatma Akyel; Fatih Dede; Tolga Yildirim; Didem Turgut; Eyup Koc; Ibrahim C. Haznedaroglu
Familial Mediterranean fever (FMF) is an inflammatory disorder that is leading cause of secondary amyloidosis (AA). This study was designed to investigate the level of mean platelet volume (MPV) in AA. Seventy-four FMF, 29 AA patients and 180 healthy controls, were included. There was no significant difference between the cases in terms of sex and age. MPV levels were measured in all groups. In the FMF group, MPV level was significantly higher when compared to the control group. MPV level was significantly lower in AA group in comparison with the FMF and healthy control groups. In summary, our present study showed low MPV values in AA due to FMF.
Renal Failure | 2015
Serhan Piskinpasa; Kemal Agbaht; Hadim Akoglu; Fatma Akyel; Nihal Ozkayar; Ezgi Yenigun Coskun; Didem Turgut; Eyup Koc; Ali Riza Odabas; Fatih Dede
Abstract Aim: To investigate the nature of dyslipidemia and its diversity in patients with systemic AA amyloidosis. Methods: The reports of the kidney biopsies performed due to nephrotic proteinuria (>3.5 g/day/1.73 m2) with preserved renal function [glomerular filtration rate (GFR) >60 mL/min/1.73 m2] were reviewed. Clinical and laboratory data of the patients with systemic AA amyloidosis and primary glomerulonephritis (PG) were analyzed. Results: A total of 104 (systemic AA amyloidosis: 43, PG: 61) patients were included in the study. Proteinuria and GFR levels were similar in both the groups. Patients with systemic AA amyloidosis group had lower serum albumin (p = 0.002), lower hemoglobin levels (p = 0.001), higher platelet counts (p = 0.002) and higher C-reactive protein levels (p = 0.001) compared to patients in PG group. Although the frequency of dyslipidemia was similar in the groups (86.0 vs. 93.4%), patients with systemic amyloidosis had both lower values of LDL-C (4.56 ± 2.05 vs. 5.49 ± 2.23 mmol/L, p = 0.028) and HDL-C (1.19 ± 0.36 vs. 1.35 ± 0.39 mmol/L, p = 0.035). Serum lipid levels were correlated with serum total protein, albumin and proteinuria levels in PG group. However, in the systemic amyloidosis group, only one clear correlation between serum lipid and hemoglobin levels was estimated. A multivariate analysis demonstrated that LDL-C was independently associated with the etiology of nephrotic proteinuria, serum total protein, serum albumin (inversely) and hemoglobin levels. Conclusions: Although dyslipidemia is closely associated with serum total protein, albumin and proteinuria in patients with PG, there is no clear such association in patients with systemic amyloidosis. Correlation between serum lipid and hemoglobin levels in this group and other findings point out that probably complex mechanisms take place in dyslipidemia of nephrotic syndrome caused by systemic AA amyloidosis.
Turkiye Klinikleri Journal of Internal Medicine | 2016
Şimal Köksal Cevher; Ezgi Çoşkun Yenigün; Ramazan Ozturk; Didem Turgut; Nihal Ozkayar; Nergiz Bayrakci; Fatih Dede
Retroperitoneal fibrosis is a rare disease of unclear etiology, which is characterized by a chronic non-specific inflammation of the retroperitoneum and development of fibrosclerotic tissues involving retroperitoneal structures. The early symptoms are non-specific and an accurate diagnosis is often achieved only subsequent to urological obstruction or the occurrence of renal failure. Kidney injury frequently disappears after renal obstruction is removed. However, in the cases where renal functions do not recover though renal obstruction is removed, renal biopsy should be applied by taking into account that intrinsic causes such as tubulointerstitial nephritis may accompany the table as well. In this report, we presented a case -along with the literaturewho admitted with acute kidney injury and for whom bilateral hydronephrose is detected based on retroperitoneal fibrosis and whose renal biopsy reveals tubulointerstitial nephritis.
Archives of Medical Science | 2015
Fatih Dede; Deniz Ayli; İpek Işık Gönül; Osman Yuksel; Ramazan Ozturk; Ayla Yildiz; Ezgi Coskun Yenigun; Serhan Piskinpasa; Didem Turgut; Eyup Koc; Ali Riza Odabas
Introduction Glomerulonephritis is still the primary cause among the diseases causing end stage renal disease. Helicobacter pylori (HP), also having a local proinflammatory effect on gastric mucosa, can trigger a local and systemic inflammatory response, and consequently have a role in the development of extragastrointestinal defects. Material and methods The study was composed of patients diagnosed with primary glomerulonephritis who had dyspeptic complaints throughout the diagnosis. Patients who received endoscopic biopsy upon the determination of pathologic findings in their upper gastrointestinal endoscopy were HP positive in their biopsy material. A triple eradication therapy was initiated for HP. Results The study included 14 female and 19 male patients, 33 in total, whose biopsy material was determined to be HP positive. Before the eradication for HP, we found serum albumin to be 34.0 (19.0–51.0) g/l, serum total protein 58.6 ±12.9 g/l, serum creatinine 0.9 (0.5–1.2) and proteinuria 3069 (652–12392) mg/day in 24-hour urine. After the eradication, however, serum albumin was found to be 40 (20–52) g/l, serum total protein 62.3 ±11.1 g/l, serum creatinine 1.02 (0.6–1.29) mg/dl and proteinuria was 2850 (172–15181) mg/day in 24-hour urine. A comparison of the results showed that a statistically significant difference is established between the serum albumin, total protein and creatinine values (p = 0.001, p = 0.001 and p = 0.021, respectively), but not between proteinuria values in 24-hour urine (p = 0.990). Conclusions Patients with primary glomerulonephritis, HP eradication treatment has an effect on serum albumin levels.
Turkish Nephrology Dialysis Transplantation | 2014
Serhan Piskinpasa; Hadim Akoglu; Nihal Ozkayar; Fatma Akyel; Didem Turgut; Fatih Dede
A 42-year-old female with history of surgery due to urolithiasis was admitted to hospital with complaints of fever, left fl ank pain and vomiting. She was found to have acute kidney injury due to urinary tract infection. Abdominal computed tomography revealed right atrophic kidney and left renal and perirenal abscesses together with urolithiasis. Urine, blood and abscess cultures yielded C. albicans. The patient was treated with fl uconazole and percutaneous drainage of the perirenal abscess, which was 60 mm in diameter. Her serum creatinine returned to the normal ranges within two weeks of hospitalization. Nearly 18 months following this presentation, she has normal serum creatinine and no abscesses in the
Nephron Clinical Practice | 2011
Sérgio Gardano Elias Bucharles; Silvio H. Barberato; Andréa E. M. Stinghen; Betina Gruber; Henrique Meister; Andrieli Mehl; Luciana Piekala; Ana C. Dambiski; Admar Souza; Marcia Olandoski; Usama Elewa; Ana Maria Sandri; Stacey A. Rizza; Fernando C. Fervenza; Akira Fujimori; Shioko Okada; Makoto Sakai; Katsuyuki Tome; Masafumi Fukagawa; Timothy Ellam; Marlies Noordzij; Friedo W. Dekker; Carmine Zoccali; Kitty J. Jager; Constança Margarida Sampaio Cruz; Roberto Pecoits-Filho; David Packham; Sara E. Ivory; Anne T. Reutens; Rory Wolfe
Clinical Nephrology Guidelines J. Cunningham, London G. Eknoyan, Houston, Tex. A. Khwaja, Sheffield Clinical Appraisal/Evidence Based Nephrology A.K. El-Sherif, Ismailia R.J. Glassock, Laguna Niguel, Calif. A. Meyrier, Paris Global CKD G. Remuzzi, Bergamo N. Perico, Bergamo R. Atkins, Melbourne, Vic. Clinical Trials D. de Zeeuw, Groningen F. Locatelli, Lecco D. Wheeler, London Continuing Nephrology Education R. Barsoum, Cairo M. Field, Sydney, N.S.W. C. Zoccali, Reggio Calabria Clinico-Pathological Conferences T.H. Jafar, Karachi Editor-in-Chief
The Breast | 2010
Isilay Kalan; Didem Turgut; Sercan Aksoy; Didem Sener Dede; Omer Dizdar; Yavuz Ozisik; Kadri Altundag